Clinical trials: HIV -1 Infection
HIV Infection
Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)
In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral…
- Trial name
- MULTIVIR2025 (NCT06842706)
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
The purpose of this study is to find out whether three different anti-HIV vaccines are safe and whether they help prevent HIV infection. These vaccines are called vCP205, vCP1433, and vCP1452.
- Trial name
- NCT00000904
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2, ALVAC(1)120(B,MN)GNP (vCP1433)
- Where
- 6 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
A Study to Test Three Experimental HIV Vaccines in Healthy Adults.
HIV-CORE 006 is a Phase 1 double-blind placebo-controlled trial, in which the mosaic immunogens are delivered by a prime-boost regimen of non-replicating simian adenovirus followed by non-replicating poxvirus MVA.
- Trial name
- HIV-CORE 006 (NCT04553016)
- Testing
- Vaccine
- Where
- 4 sites in Kenya, Uganda and 1 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV-1-infection
Advanced HIV: Outcomes for Rapid ART
AHORA is designed as a single-arm, open label, non-comparative, real-world prospective, observational study evaluating the outcomes for viral control and CD4 recovery/immune reconstitution in predominantly Hispanic/Latinx…
- Trial name
- AHORA (NCT05526118)
- Testing
- Bictegravir/emtricitabine/tenofovir alafenamide
- Volunteers
- 50 people
- Sponsor
- Valley AIDS Council
Infection, Human Immunodeficiency Virus
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
GSK1349572 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase IIa, multicenter, randomized, parallel, double-blind, dose ranging, placebo-controlled 'proof of concept' study is to be…
- Trial name
- NCT00708110
- Testing
- GSK1349572
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- ViiV Healthcare
HIV Disease, Herpes Simplex 1
A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects
This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral…
- Conditions
- HIV Disease, Herpes Simplex 1, Herpes Simplex 2
- Trial name
- HSVHIV (NCT05823779)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Global Research Institute
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/cobicistat (COBI [GS-9350])/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus efavirenz…
- Trial name
- NCT01095796
- Testing
- Stribild, Atripla
- Where
- 102 sites in United States, Puerto Rico
- Volunteers
- 707 people
- Sponsor
- Gilead Sciences
HIV Infections
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
The primary objective was to evaluate the antiviral activity and safety of two regimens of tipranavir (500 mg BID or 1000 mg BID) plus ritonavir (100 mg BID) administered in combination with 1 new nucleoside reverse transcriptase…
- Trial name
- NCT02238314
- Testing
- Tipranavir low dose, Tipranavir high dose, Ritonavir
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Telemedicine, HIV-1-infection
Telemedicine in HIV Care in Buenos Aires
The aim of this investigation is to conduct an implementation research to facilitate and evaluate the implementation of VCT((Videoconsult through telemedicine) among HIV HCP(healthcare providers) and PLWH(people living with HIV)
- Trial name
- NCT04513496
- Volunteers
- 4,000 people
- Sponsor
- Fundacion Ibis
HIV-1 Infection
Pomalidomide as an Immune-enhancing Agent for the Control of HIV
This study is designed to evaluate the safety and efficacy of pomalidomide in HIV-1-infected individuals on ART and to determine the impact of pomalidomide on virological control in people living with HIV during an analytical…
- Trial name
- PEACH (NCT06660498)
- Testing
- Pomalidomide 2 mg, Aspirin 75 mg
- Where
- 2 sites in Australia, Denmark
- Volunteers
- 32 people
- Sponsor
- University of Aarhus
HIV Infections, Lipodystrophy
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus…
- Trial name
- NCT00005764
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
HIV Infections, HIV-1
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a background regimen…
- Trial name
- NCT00543725
- Testing
- TMC278, efavirenz
- Where
- 82 sites in United States, Australia and 18 more
- Volunteers
- 680 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
To obtain safety and efficacy data for antiretroviral regimens containing emtricitabine in HIV-1 infected pediatric subjects. To determine emtricitabine concentrations in HIV-1 infected pediatric subjects and, if necessary, to…
- Trial name
- NCT00642291
- Testing
- Emtricitabine
- Where
- 2 sites in Romania
- Volunteers
- 16 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
The purpose of the study is to determine the safety of and immune response to the investigational HIV vaccine, EP HIV-1090, in HIV uninfected adults.
- Trial name
- NCT00141024
- Testing
- EP HIV-1043, EP HIV-1090
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants
This is a phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir and rilpivirine in plasma following the administration of a single 600 milligram (mg) and a 900 mg intramuscular (IM)…
- Trial name
- NCT04371380
- Testing
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir extended release suspension for injection (long-acting)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers
Tat is a key HIV regulatory protein produced very early after infection, prior to virus integration, and necessary for viral gene expression, cell-to-cell virus transmission and disease progression.
- Trial name
- ISS T-003 (NCT01513135)
- Testing
- Tat
- Where
- South Africa
- Volunteers
- 200 people
- Sponsor
- Barbara Ensoli, MD
HIV Infection
Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine
Recent studies have shown that patients receiving state-of-the-art treatment for HIV infection (highly active antiretroviral therapy, or HAART) show discordant responses to therapy-that is, they improve both clinically and…
- Trial name
- NCT00026676
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
The primary objectives are to assess the antiviral activity, clinical safety and tolerability parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the 1-week induction period treatment period.
- Trial name
- NCT04560569
- Testing
- Albuvirtide, 3BNC117 Antibody
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Frontier Biotechnologies Inc.
HIV-1 Infection, Tuberculosis
PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB
This study was done to evaluate the effect of HIV and TB treatment on a commonly used birth control method. It enrolled women who were infected with HIV and TB and were taking efavirenz (EFV; Sustiva®; an anti-HIV medication)…
- Trial name
- PRIDE-HT (NCT02412436)
- Testing
- Depot medroxyprogesterone acetate
- Where
- 5 sites in Botswana, Kenya and 2 more
- Volunteers
- 62 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections